Xtrem Biotech
-
DATABASE (56)
-
ARTICLES (44)
Founded in 1999 in Santiago de Compostela, XesGalicia SGEIC SA is 100% owned by the Galician Institute for Economic Promotion (Igape). The VC supports Spanish startups through seed funding, early ventures and growth capital investments. It usually invests between €60,000 and €200,000 in each enterprise, with temporary acquisition of minority stakes. The firm focuses on the biotech, telecommunications, energy and environment sectors. In 2014, it was involved in the creation of the Galician Network of Business Angels to facilitate the collaboration of private and public fund investors to nurture innovative projects and applications of new technologies.
Founded in 1999 in Santiago de Compostela, XesGalicia SGEIC SA is 100% owned by the Galician Institute for Economic Promotion (Igape). The VC supports Spanish startups through seed funding, early ventures and growth capital investments. It usually invests between €60,000 and €200,000 in each enterprise, with temporary acquisition of minority stakes. The firm focuses on the biotech, telecommunications, energy and environment sectors. In 2014, it was involved in the creation of the Galician Network of Business Angels to facilitate the collaboration of private and public fund investors to nurture innovative projects and applications of new technologies.
Established in 1958, VERSO Capital is a boutique merchant banking and financial services firm based in Luxembourg. It also has offices in Geneva, Fribourg, Vaduz, Dubai, Singapore and BVI. VERSO specializes in sectors like education, food and renewables. Since 2011, the firm has invested over $700bn in venture capital in the global startup ecosystem. Funds worth over $245m were pumped into climatech, foodtech and biotech sectors since 2017. In February 2021, it merged with Swiss alternative asset manager ALDINI Capital that was also founded in 1958 and based in Switzerland and Liechtenstein. VERSO will leverage the expertise of ALDINI in hedge funds, private equity and real estate.
Established in 1958, VERSO Capital is a boutique merchant banking and financial services firm based in Luxembourg. It also has offices in Geneva, Fribourg, Vaduz, Dubai, Singapore and BVI. VERSO specializes in sectors like education, food and renewables. Since 2011, the firm has invested over $700bn in venture capital in the global startup ecosystem. Funds worth over $245m were pumped into climatech, foodtech and biotech sectors since 2017. In February 2021, it merged with Swiss alternative asset manager ALDINI Capital that was also founded in 1958 and based in Switzerland and Liechtenstein. VERSO will leverage the expertise of ALDINI in hedge funds, private equity and real estate.
Founded in Silicon Valley by serial investor and founder of Google Ventures Bill Marris, Section 32 has multiple investment interests with medicine and biotech key amongst them. Marris himself has invested in over 500 companies, with over one-third resulting in IPO or M&A. Fifty of his portfolio companies have exceeded $1bn valuations, including Uber. Section 32 currently has 48 companies in its portfolio. Its most recent investments have included in Canadian remote medicine platform Cover Health’s $43m Series B round and in the $100m Series B round of US cancer detection software C2i Genomics, both in April 2021. In March 2021, it participated in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Founded in Silicon Valley by serial investor and founder of Google Ventures Bill Marris, Section 32 has multiple investment interests with medicine and biotech key amongst them. Marris himself has invested in over 500 companies, with over one-third resulting in IPO or M&A. Fifty of his portfolio companies have exceeded $1bn valuations, including Uber. Section 32 currently has 48 companies in its portfolio. Its most recent investments have included in Canadian remote medicine platform Cover Health’s $43m Series B round and in the $100m Series B round of US cancer detection software C2i Genomics, both in April 2021. In March 2021, it participated in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Advisor, board member, co-founder of NovoNutrients
Brian Sefton has been co-founder, a board member and a part-time advisor at NovoNutrients, a San Francisco-based biotech manufacturer of alt-protein produced from fermentation and CO2 since it was founded in 2017. In 2009, he co-founded research entity Oakbio, from which NovoNutrients evolved, and was its President and CTO. Sefton was CTO and President at NovoNutrients and also co-CEO and Chief Scientist at Oakbio until 2021 when he became the CEO at San Francisco-based fermentation commercialization startup Sincarne. Between 2005 and 2011, Sefton was also CEO at pharma research company Pharmadyn, working on drugs development for Alzheimer's Disease, and, for three of those years, was also Managing Partner of Stratsyn, a consultancy specializing in creation, development, management and fund raising for not-for-profit organizations. Sefton’s earlier posts include: directing nanotechnology commercialization and investment company Nanosig for three years, CEO of Silicon Valley’s Fastlane, a high-profile pioneer in real-time network traffic and security analysis for six years; and, simultaneously, being CEO at Bluebox Communications, developing high-end network security applications and appliances for Fortune 500 companies and the US government.Sefton holds an MBA from Santa Clara University in California and a bachelor’s degree in biochemistry from the University of California, Berkeley
Brian Sefton has been co-founder, a board member and a part-time advisor at NovoNutrients, a San Francisco-based biotech manufacturer of alt-protein produced from fermentation and CO2 since it was founded in 2017. In 2009, he co-founded research entity Oakbio, from which NovoNutrients evolved, and was its President and CTO. Sefton was CTO and President at NovoNutrients and also co-CEO and Chief Scientist at Oakbio until 2021 when he became the CEO at San Francisco-based fermentation commercialization startup Sincarne. Between 2005 and 2011, Sefton was also CEO at pharma research company Pharmadyn, working on drugs development for Alzheimer's Disease, and, for three of those years, was also Managing Partner of Stratsyn, a consultancy specializing in creation, development, management and fund raising for not-for-profit organizations. Sefton’s earlier posts include: directing nanotechnology commercialization and investment company Nanosig for three years, CEO of Silicon Valley’s Fastlane, a high-profile pioneer in real-time network traffic and security analysis for six years; and, simultaneously, being CEO at Bluebox Communications, developing high-end network security applications and appliances for Fortune 500 companies and the US government.Sefton holds an MBA from Santa Clara University in California and a bachelor’s degree in biochemistry from the University of California, Berkeley
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Launched in 2015 in Brussels, EIT Food was established by the not-for-profit European Institute of Innovation & Technology (EIT) and funded by the European Union as an investor and accelerator. Its aim is to support mainly European startups in foodtech areas ranging from traceability to alternative proteins, with sustainability a key deciding factor in the startups it backs from pre-seed to Series-B level. The organization currently has 55 startups in its portfolio, which raised more than €91m in investments in 2020. Its most recent investments include 700,000 Swiss francs (€637,000) in the seed round in January 2021 of Swiss biotech SwissDeCode, a company that applies DNA testing to food traceability. Another investment was the December 2020 €900,000 seed round of Spanish compostable-packaging tech Food Sourcing Specialists.
Launched in 2015 in Brussels, EIT Food was established by the not-for-profit European Institute of Innovation & Technology (EIT) and funded by the European Union as an investor and accelerator. Its aim is to support mainly European startups in foodtech areas ranging from traceability to alternative proteins, with sustainability a key deciding factor in the startups it backs from pre-seed to Series-B level. The organization currently has 55 startups in its portfolio, which raised more than €91m in investments in 2020. Its most recent investments include 700,000 Swiss francs (€637,000) in the seed round in January 2021 of Swiss biotech SwissDeCode, a company that applies DNA testing to food traceability. Another investment was the December 2020 €900,000 seed round of Spanish compostable-packaging tech Food Sourcing Specialists.
This Luxembourg-based venture capital firm was established in 2004 and has offices in Silicon Valley and Madrid, managing over €170 million in capital. It invests in early-stage, deeptech companies in the Iberian peninsula, France, the UK, and Ireland. The VC has a particular focus on AI, cybersecurity and big data. In 2019, it won the Spanish VC Deal of the Year 2019, alongside Caixa Capital Risc, for the sale of PlayGiga.Adara Ventures currently has 15 companies in its portfolio following eight exits totalling $1.2bn in value. Its most recent investments include leading the €2m seed round of medtech IOMED Medical Solutions, which converts medical text into extractable data, and in the €8m seed round of biotech startup QUIBIM – both Spanish companies.
This Luxembourg-based venture capital firm was established in 2004 and has offices in Silicon Valley and Madrid, managing over €170 million in capital. It invests in early-stage, deeptech companies in the Iberian peninsula, France, the UK, and Ireland. The VC has a particular focus on AI, cybersecurity and big data. In 2019, it won the Spanish VC Deal of the Year 2019, alongside Caixa Capital Risc, for the sale of PlayGiga.Adara Ventures currently has 15 companies in its portfolio following eight exits totalling $1.2bn in value. Its most recent investments include leading the €2m seed round of medtech IOMED Medical Solutions, which converts medical text into extractable data, and in the €8m seed round of biotech startup QUIBIM – both Spanish companies.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Mayfield Fund is one of Silicon Valley's oldest venture capital firms. Founded by Wally Davis and Thomas J Davis Jr in 1969, the VC is based in Menlo Park, California.Current investments include CRISPR-focused companies like Mammoth Biosciences and biotech startup iLoF,l which is focused on creating a digital library of optical fingerprints for non-invasive patient screening, early diagnostics and personalized medical treatments.. With a total of $2.5bn assets under management, the firm focuses mainly on early-stage to growth-stage investments. The VC has also backed startups like Marketo, Lyft and SolarCity. Most of Mayfield’s exits took place during the 2008 financial crisis and through subsequent funds.In April 2020, amid the Covid-19 pandemic, Mayfield announced two new funds which raised $750m in total. Mayfield XVI will invest in early-stage companies, while Mayfield Select II will focus on growth-stage companies outside its portfolio. The company said last year that it has raised a similar size fund every four years and has invested in 30 companies per fund. It primarily leads Series A investments.
Mayfield Fund is one of Silicon Valley's oldest venture capital firms. Founded by Wally Davis and Thomas J Davis Jr in 1969, the VC is based in Menlo Park, California.Current investments include CRISPR-focused companies like Mammoth Biosciences and biotech startup iLoF,l which is focused on creating a digital library of optical fingerprints for non-invasive patient screening, early diagnostics and personalized medical treatments.. With a total of $2.5bn assets under management, the firm focuses mainly on early-stage to growth-stage investments. The VC has also backed startups like Marketo, Lyft and SolarCity. Most of Mayfield’s exits took place during the 2008 financial crisis and through subsequent funds.In April 2020, amid the Covid-19 pandemic, Mayfield announced two new funds which raised $750m in total. Mayfield XVI will invest in early-stage companies, while Mayfield Select II will focus on growth-stage companies outside its portfolio. The company said last year that it has raised a similar size fund every four years and has invested in 30 companies per fund. It primarily leads Series A investments.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Tony Fadell is the inventor of the iPod, co-inventor of the iPhone, and former CEO and founder of Nest Labs, which was later acquired by Google. He is also an angel investor and head of Paris-based deeptech advisory and investing firm Future Shape, which has over 200 companies in its portfolio and a focus on issues like the electrification and digital connection of things, biomanufacturing and the eradication of waste. Fadell has invested in at least 10 startups, with his most recent disclosed investments having taken place in 4Q20. These included his participation in the $7m seed round of London-based consumer technology and conceptual design house Nothing, the $45m Series B round of US biotech firm and vegan leather maker MycoWorks, well as the $31m Series A round of video call effects and presentation tools company mmhmm.
Tony Fadell is the inventor of the iPod, co-inventor of the iPhone, and former CEO and founder of Nest Labs, which was later acquired by Google. He is also an angel investor and head of Paris-based deeptech advisory and investing firm Future Shape, which has over 200 companies in its portfolio and a focus on issues like the electrification and digital connection of things, biomanufacturing and the eradication of waste. Fadell has invested in at least 10 startups, with his most recent disclosed investments having taken place in 4Q20. These included his participation in the $7m seed round of London-based consumer technology and conceptual design house Nothing, the $45m Series B round of US biotech firm and vegan leather maker MycoWorks, well as the $31m Series A round of video call effects and presentation tools company mmhmm.
Xtrem Biotech, an agritech startup from Granada, seeks global expansion
With its research roots in the University of Granada, Xtrem Biotech was named one of the world's most innovative agtech spin-offs by accelerator TERRA Food & AgTech
Daniel Oliver: Building a "Facebook" for investments in biotech startups
The biologist and crowdfunding expert has pioneered the growth of Spanish biotech startups, providing access to early-stage investments, with support from scientific experts worldwide
Meatable: Cell-based meat startup secures $47m Series A for scalable technology
The Dutch startup offers a pioneering technology for quickly scaling cell-based meat production while eliminating the need for animal-derived growth media
Forget solar panels and batteries, Bioo wants to scale soil bioelectricity generation
Improving on NASA’s microbial fuel cell tech, Bioo hopes to boost crop efficiency and transform the way urbanites live, in future green cities powered by plants
TurtleTree Labs: Creating sustainable mammalian milk alternatives from stem cells
Founder’s search for high-quality dairy milk led to the creation in a lab of naturally occurring ingredients found in human milk for supply to dairy milk and infant formula businesses
Sequoia Capital China holds steady with investments in healthcare, biotech and green economy
China’s most active investor increases bets on sectors beyond the consumer internet and edtech recently hurt by regulatory clampdown
Because Animals: Pioneering cultured meat for pets
The biotech startup is disrupting the pet food processing industry with cell-based food to minimize environmental “pawprints” and promote animal welfare
NovoNutrients: Tackling the dual problems of CO2 emissions and over-fishing
The first to transform CO2 to fish food, NovoNutrients is trialing with industry giants Skretting and Chevron, and will soon raise Series A funding
Poliloop: Tackling pollution crisis with plastic-eating bacteria for industrial use
Hungarian biotech Poliloop is closing $2m seed funding for “bacteria cocktail” that breaks down plastic into organic waste quickly, enabling more affordable and eco-friendly waste management
Qorium: Lab-grown premium leather for the future of luxury
The Dutch biotech startup co-founded by cell-based meat pioneer Mark Post is targeting the luxury goods market with its “clean leather” sheets made from cultivating bovine skin cells, and plans to raise up to €100m
Mycorena: Fungi-based vegan protein challenging traditional plant-based ingredients
Award-winning Swedish biotech startup is scaling production of mycoprotein to become a key player in the emerging market for functional proteins
TreeFrog Therapeutics: Mimicking how stem cells grow in the human body
The French biotech’s proprietory technology to cultivate pluripotent stem cells in a 3D environment can be scaled to mass-produce high-quality cells to treat diseases such as Parkinson’s
New Food Invest: Opportunities in the European alt-protein space
With a record €2.4bn investment in 2019, Europe’s foodtech sector appears poised for continued growth, but startups, corporations, governments and even universities can do more, experts say
Future Food Asia by ID Capital: Introducing Asia's agrifood startups to the world
More than a meeting of startups and investors, the conference showcases ID Capital’s investment thesis and Big Ag’s support for agrifood tech in the world’s most populous region
Cubiq Foods: Bioreactor farms producing the food of tomorrow
Growing appetite for meat alternatives expected to fuel demand for Cubiq’s low calorie, Omega 3-enriched lab-grown fats
Sorry, we couldn’t find any matches for“Xtrem Biotech”.
POPULAR DATABASE
